KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $720.0 million.

  • Bio-Rad Laboratories' Net Income towards Common Stockholders rose 20058.68% to $720.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $759.9 million, marking a year-over-year increase of 14120.49%. This contributed to the annual value of $759.9 million for FY2025, which is 14120.49% up from last year.
  • As of Q4 2025, Bio-Rad Laboratories' Net Income towards Common Stockholders stood at $720.0 million, which was up 20058.68% from -$341.9 million recorded in Q3 2025.
  • Bio-Rad Laboratories' 5-year Net Income towards Common Stockholders high stood at $3.9 billion for Q3 2021, and its period low was -$3.4 billion during Q1 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $87.6 million (2023), whereas its average is -$54.7 million.
  • In the last 5 years, Bio-Rad Laboratories' Net Income towards Common Stockholders crashed by 44451.59% in 2022 and then skyrocketed by 51473.6% in 2024.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' Net Income towards Common Stockholders stood at -$1.6 billion in 2021, then skyrocketed by 152.89% to $827.8 million in 2022, then plummeted by 57.75% to $349.7 million in 2023, then plummeted by 304.67% to -$715.8 million in 2024, then surged by 200.59% to $720.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at $720.0 million for Q4 2025, versus -$341.9 million for Q3 2025 and $317.8 million for Q2 2025.